<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0005558'>Chronic Leukemia</z:hpo> Working Party of the EBMT has collected data on 118 patients of median age 24 years (range 0.3 to 53 years) who underwent an allogeneic bone marrow transplantation from unrelated donors for treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, n = 24; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, n = 26; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t, n = 34; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, n = 12; sAML, n = 22) between 1986 and 1996 </plain></SENT>
<SENT sid="1" pm="."><plain>The data were reported by 49 EBMT centers </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-four of 118 patients are alive, relapse was the cause of <z:hpo ids='HP_0011420'>death</z:hpo> in 19 of 84 patients and the remaining patients died of transplant-related mortality </plain></SENT>
<SENT sid="3" pm="."><plain>For the whole group the actuarial probability of survival at 2 years is 28%, disease-free survival 28%, relapse risk 35% and transplant-related mortality is 58% </plain></SENT>
<SENT sid="4" pm="."><plain>The transplant-related mortality is significantly influenced by the age of the recipient (&lt;18 years 40%, 18-35 years 61%, &gt;35 years 81%) </plain></SENT>
<SENT sid="5" pm="."><plain>The relapse rate after BMT is influenced by FAB classification of the disease at BMT </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with a low blast count (RA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) have a lower probability of relapse (13%, 15%) compared to patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t or sAML (29%, 45%) </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, we found evidence of a graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> effect in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/sAML </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD, grade II-IV, had a probability of relapse of 26% vs 42% in patients with no <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD or grade I only </plain></SENT>
<SENT sid="9" pm="."><plain>Allogeneic transplantation with an HLA-matched, unrelated donor may be offered to younger patients (age &lt;35 years) with poor risk <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> or <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
</text></document>